← Back to Clinical Trials
Recruiting NCT05638464

NCT05638464 Multisite Transcranial Direct Current Stimulation to Promote Hand Function Recovery After Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05638464
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2021-08-13
Primary Completion 2024-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
multisite HD-tDCS EMG-driven robot handSham HD-tDCS EMG-driven robot hand

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2021-08-13 with a primary completion date of 2024-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A novel multisite high definition tDCS (HD-tDCS) in healthy people showed that such network-targeted stimulation could enhance motor excitability beyond traditional stimulation which targeting only one region. It showed that the excitability following multisite HD-tDCS was more than double the increase following conventional tDCS. To consider the various lesion site of different stroke survivors. The electrode placements based on personalized lesion profiles and anatomical features can be determined using finite element modeling, with lesion profiles generated from fMRI and advanced algorithms calculating the current density to maximize the modulation effect. Combining motor network interaction and the new multisite electrode montage may further provide a potential to facilitate stroke recovery.

Eligibility Criteria

Inclusion Criteria: * first-ever stroke, the duration after stroke exceeds 12 months; * mild to moderate upper extremity motor function deficit, determined by the Fugl-meyer assessment of upper extremity (FMAUE) scores between 15 and 53; * detectable voluntary muscle sEMG signal from flexor digitorum (FD) and extensor digitorum (ED); * scored below 3 in the Modified Ashworh Score (MAS) of FD and ED; * sufficient cognitive function to follow the assessment and training instructions, determined by Mini Mental State Examination score of more than 21. Exclusion Criteria: * history of epilepsy, or any other contradictions of brain stimulation; * severe joint contracture of elbow or shoulder, or pain induced by any other neurological, neuromuscular, and orthopedic diseases.

Contact & Investigator

Central Contact

Raymond Kai-yu Tong, PhD

✉ kytong@cuhk.edu.hk

📞 +852 3943 8454

Principal Investigator

Raymond Kai-yu Tong, PhD

PRINCIPAL INVESTIGATOR

Department of Biomedical Engineering, CUHK

Frequently Asked Questions

Who can join the NCT05638464 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05638464 currently recruiting?

Yes, NCT05638464 is actively recruiting participants. Contact the research team at kytong@cuhk.edu.hk for enrollment information.

Where is the NCT05638464 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT05638464 clinical trial?

NCT05638464 is sponsored by Chinese University of Hong Kong. The principal investigator is Raymond Kai-yu Tong, PhD at Department of Biomedical Engineering, CUHK. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology